On this page
- Quick reference
- Dosage chart and four steps
- Supplies needed
- Vial and research context
- Protocol Overview
- Dosing Protocol
- Storage Instructions
- Important Notes
- How This Works
- Potential Benefits & Side Effects
- Lifestyle Factors
- Injection Technique
- Recommended Source
- Important Note
- Sources and Further Reading
- Related research, protocols, and guides
Thymosin Alpha-1 Quick Reference (5 mg Vial)
- Vial contents
- 5 mg Thymosin Alpha-1
- Final volume
- 3 mL
- Concentration
- 1.67 mg/mL
- One U-100 unit
- 16.67 mcg in 0.01 mL
Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read Thymosin Alpha-1 Peptide: Benefits, Uses, Side Effects, Dosage, and Research.
Thymosin Alpha-1 Dosage Chart
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~1.67 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 300 mcg (0.3 mg) | 18 units (0.18 mL) |
| Weeks 2–8 | 500 mcg (0.5 mg) | 30 units (0.30 mL) |
Frequency: Inject once daily subcutaneously. This 8‑week protocol begins at 300 mcg to assess tolerance, then increases to a maintenance dose of 500 mcg daily from Week 2 onward. The 500 mcg daily dose yields ~3.5 mg/week, consistent with clinical dosing ranges[4][5]. Treatment durations of 8–16 weeks are commonly reported in literature.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (Thymosin Alpha-1, 5 mg each):
- 8 weeks: approximately 6 vials required
- 12 weeks: approximately 9 vials required
- 16 weeks: approximately 12 vials required
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (6 vials): 18 mL — 2 bottles required (10 mL each)
- 12 weeks (9 vials): 27 mL — 3 bottles required (10 mL each)
- 16 weeks (12 vials): 36 mL — 4 bottles required (10 mL each)
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs — 2 boxes required (100 swabs each)
- 12 weeks: 168 swabs — 2 boxes required (100 swabs each)
- 16 weeks: 224 swabs — 3 boxes required (100 swabs each)
PeptideDosages has no affiliation with Pure Lab Peptides and receives no commission from these Pure Lab links. Supplier pages are not scientific evidence or proof of suitability for human use.
Thymosin Alpha-1 Vial and Research Context
- Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
- Typical daily range: 300–500 mcg once daily (gradual titration).
- Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F); after reconstitution, refrigerate and use within 7 days.
Thymosin Alpha-1 (Tα1) is a 28–amino acid peptide originally isolated from the thymus gland, recognized for its broad immunomodulatory properties[1]. It has been investigated as an immune enhancer in chronic viral infections (hepatitis B/C, HIV/AIDS) and critical illness (sepsis, COVID-19)[2][3]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.
Protocol Overview
Concise summary of the once‑daily regimen.
- Goal: Support immune modulation and enhance host defense mechanisms[1][2].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 300–500 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; use within 7 days.
Dosing Protocol
Suggested daily titration approach.
- Start: 300 mcg daily for Week 1 to assess tolerance.
- Target: 500 mcg daily from Week 2 onward.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at 2–8 °C (35.6–46.4 °F) for short-term or −20 °C (−4 °F) for long-term; minimize moisture exposure[5].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 7 days when using bacteriostatic water; avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose and site rotation to maintain consistency.
- Inspect solution before each use—do not use if cloudy or discolored.
How This Works
Thymosin Alpha-1 is a naturally occurring thymic peptide that modulates immune function through multiple pathways[1]. It enhances the maturation and differentiation of T‑cells, augments dendritic cell function, and promotes the production of key cytokines including interferon‑α and interleukin‑2[2][6]. Clinical studies have demonstrated Tα1’s ability to enhance immune responses in immunocompromised individuals, including those with chronic hepatitis B and C infections[4]. Meta-analyses have also shown benefit in reducing mortality in moderate-to-critical COVID-19 patients[3].
Potential Benefits & Side Effects
Observations from preclinical and clinical literature.
- Supports enhanced T‑cell function and overall immune competence[1][2].
- Demonstrates an excellent safety profile; doses up to 1.6 mg twice weekly for 6–12 months have been well-tolerated[4][7].
- Even at experimental doses up to 16 mg SC over 12 months, no significant Tα1‑specific toxicity has been observed[7].
- Most common adverse effect is mild injection‑site irritation (redness or discomfort).
Lifestyle Factors
Complementary strategies for best outcomes.
- Maintain adequate sleep and stress management to support immune function.
- Consume a nutrient‑dense diet rich in vitamins C, D, and zinc.
- Engage in moderate physical activity to complement immune optimization.
- Avoid excessive alcohol and smoking, which impair immune responses.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[8].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[9][10].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[9].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[11].
Recommended Source
We recommend Pure Lab Peptides for high‑purity Thymosin Alpha-1 (5 mg).
Why Pure Lab Peptides?
- High‑purity, third‑party‑tested lots with batch COAs.
- Consistent, ISO‑aligned handling and documentation.
- Reliable fulfillment to maintain cold‑chain integrity.
Important Note
This content is for educational purposes only and is not medical advice.
Sources and Further Reading
- 1
World Journal of Virology
— Dominari et al. (2020): Comprehensive review of Thymosin Alpha-1 mechanisms, dosing (0.8–6.4 mg SC), and clinical applications - 2
Molecules (MDPI)
— Tao et al. (2023): Thymosin Alpha-1 in viral diseases—mechanisms and therapeutic applications in HBV, HCV, and HIV - 3
Inflammopharmacology
— Soeroto et al. (2023): Meta-analysis of Tα1 in COVID-19; significant mortality reduction in moderate-to-critical patients - 4
Expert Opinion on Biological Therapy
— Thymalfasin (Zadaxin) clinical overview: 1.6 mg SC twice weekly for hepatitis B treatment - 5
Annals of the New York Academy of Sciences
— Thymosin Alpha-1: biological activities, clinical applications, and pharmacokinetics review - 6
Clinical Immunology
— Mechanisms of thymosin alpha-1 immunomodulation: T-cell maturation and cytokine production - 7
FDA Peptide Advisory Committee (2024)
— Safety data: Tα1 doses up to 16 mg SC for 12 months showed no significant toxicity - 8
Hospital Pharmacy
— Jordan et al. (2021): Small-volume injection accuracy; recommends ≥20% syringe capacity for precision - 9
CDC
— Vaccine administration: subcutaneous route (angle/site; no aspiration required) - 10
Johns Hopkins Arthritis Center
— How to give a subcutaneous injection: site selection, rotation, and technique - 11
NCBI Bookshelf
— Best practices for injection: asepsis, preparation, site rotation, and administration - 13
Pure Lab Peptides
— Thymosin Alpha-1 (5 mg) product page (quality and batch documentation) - 13
Subcutaneous Drug Injection Review (PMC)
— Pharmacologic considerations of the subcutaneous route - 14Phase 3 TESTS Thymosin Alpha-1 Sepsis Trial, PMID 39814420 - Primary 1,106-person study using 1.6 mg SC every 12 hours for seven days after reconstitution in 1 mL sterile water.
- 15ETASS Severe Sepsis Trial - Primary trial using 1.6 mg SC twice daily for five days and once daily for two days.
- 16Zadaxin HIV Immunologic-Nonresponder Trial - Primary study using 1.6 mg SC daily for two weeks and then twice weekly for 22 weeks.
Related research, protocols, and guides
Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.
Other vial-strength protocols